SCHEMBL2554331

SCHEMBL2554331

CC(=O)c1ccc(-c2ccccc2C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.62
MAPT P10636 1/20 0.62
LTB4R2 Q9NPC1 4/20 0.55
CDC25B P30305 1/20 0.50
ATM Q13315 1/20 0.50
HNF4A P41235 1/20 0.50
AKR1C3 P42330 2/20 0.49
AKR1C2 P52895 2/20 0.49
AKR1B10 O60218 1/20 0.49
AKR1B1 P15121 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C1 Q04828 1/20 0.49
HSD17B1 P14061 2/20 0.49
MYC P01106 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
BCAT2 O15382 1/20 0.48
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
MAOB P27338 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10955727 0.89 SMN1; SMN2 (0.61) SMN1; SMN2MAPTLTB4R2HSD17B1MEN1
SCHEMBL70136 0.86 CDC25B (0.55) MAPTLTB4R2CDC25BATMHNF4A
SCHEMBL30292805 0.86 HNF4A (0.63) SMN1; SMN2LTB4R2CDC25BATMHNF4A
SCHEMBL18759613 0.86 HNF4A (0.63) SMN1; SMN2LTB4R2CDC25BATMHNF4A
SCHEMBL6638700 0.86 LTB4R2 (0.52) SMN1; SMN2MAPTLTB4R2CDC25BATM
SCHEMBL3104358 0.85 KDM4C (0.58) SMN1; SMN2MAPTLTB4R2CDC25BATM
Water SCHEMBL28312529 0.85 CDC25B (0.53) MAPTLTB4R2CDC25BATMHNF4A
SCHEMBL2556333 0.84 SMN1; SMN2 (0.52) SMN1; SMN2MAPTLTB4R2CDC25BATM
SCHEMBL10296041 0.84 MAPT (0.79) SMN1; SMN2MAPTHSD17B1MAOBALDH1A1
SCHEMBL11448863 0.84 MAPT (0.71) SMN1; SMN2MAPTHSD17B1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
CN-106795107-B Sulfonate compound, photoacid generator, and resin composition for lithography 三亚普罗股份有限公司 2021-05-28 CN disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
CN-106795107-A Sulfonate compound, light acid producing agent and photoetching resin combination 三亚普罗股份有限公司 2017-05-31 CN disclosed
US-20130324542-A1 [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-12-05 US disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2650293-A1 [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) 2013-10-16 EP disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 SMN1; SMN2 2504/4885MAPT 4795/4885LTB4R2 242/4885
US-20130324542-A1 [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF MET, RET, ALK SMN1; SMN2 3760/4885MAPT 1113/4885LTB4R2 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.